St. Jude's Newly Approved Axium Stimulator Could Be Market Game-Changer
This article was originally published in The Gray Sheet
St. Jude followed through on its 2015 acquisition of start-up Spinal Modulation with an FDA approval of the Axium neurostimulator for chronic intractable pain. It's the first such device to target the dorsal root ganglion and could expand the overall size of the spinal cord stimulation market.
Register for our free email digests: